1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
973 242 0005
https://www.synaptogen.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 5
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Alan J. Tuchman M.D., MBA(FAAN) | CEO & Director | 303,35k | N/A | 1947 |
Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer & Director | 375k | N/A | 1942 |
Mr. Robert Weinstein | CFO, Executive VP, Treasurer & Secretary | 568,92k | N/A | 1960 |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
El ISS Governance QualityScore de Synaptogenix, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.